deferiprone has been researched along with Transfusion Reaction in 91 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 9.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| "Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children." | 9.09 | A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 8.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 8.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 8.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| " Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)." | 8.80 | Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000) |
| "Data on the use of deferiprone in young children with iron overload are limited." | 7.83 | Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016) |
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 7.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| "Two patients experienced agranulocytosis that resolved without complications upon discontinuation of therapy." | 6.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "Deferasirox is an oral chelator." | 5.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 5.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 5.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| " The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP." | 5.13 | Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children." | 5.09 | A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000) |
| "Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate." | 4.89 | Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 4.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 4.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 4.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| " Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)." | 4.80 | Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000) |
| "Deferiprone is the most widely studied oral iron chelator and, at present, the only one shown to be effective in achieving negative iron balance in long-term clinical trials for chronic iron overload." | 4.79 | Oral iron chelation with deferiprone. ( Diav-Citrin, O; Koren, G, 1997) |
| "Data from several trials have provided direct and supportive evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major." | 4.79 | Long-term therapy with deferiprone. ( Olivieri, NF, 1996) |
| "Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and deferiprone." | 3.91 | Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. ( Gallie, BL; Olivieri, NF; Sabouhanian, A, 2019) |
| "To compare the efficacy and safety of oral iron chelators (Deferiprone and Deferasirox) when used singly and in combination in multi-transfused children with thalassemia." | 3.83 | Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. ( Gomber, S; Jain, P; Narang, M; Sharma, S, 2016) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Data on the use of deferiprone in young children with iron overload are limited." | 3.83 | Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016) |
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 3.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| "In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI." | 3.76 | Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010) |
| "Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion-dependent thalassemia." | 3.76 | Deferiprone. ( Longo, F; Massano, D; Piga, A; Roggero, S; Salussolia, I; Serra, M, 2010) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| "Two patients experienced agranulocytosis that resolved without complications upon discontinuation of therapy." | 2.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| "Deferiprone was clearly not effective in three patients (two with myelofibrosis, one with myelodysplasia)." | 2.68 | Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ( Goudsmit, R; Kersten, MJ; Lameijer, W; Lange, R; Roozendaal, KJ; Smeets, ME; Vreugdenhil, G, 1996) |
| "Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy." | 2.48 | Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012) |
| "Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States." | 2.44 | Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007) |
| "Deferasirox has a manageable safety profile with favorable patient satisfaction reports." | 2.44 | Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. ( Goldberg, SL, 2007) |
| "If untreated, iron overload is responsible for heart, liver and endocrine diseases." | 2.42 | Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003) |
| "Deferiprone has additive, or possibly synergistic, effects on iron excretion when combined with deferoxamine." | 2.40 | Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. ( Barman Balfour, JA; Foster, RH, 1999) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload." | 1.56 | Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. ( Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG, 2020) |
| "Deferasirox is an oral chelator." | 1.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 1.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "Deferiprone has been shown to be capable of reducing the iron burden in patients with β-thalassaemia." | 1.37 | Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. ( Chantharaksri, U; Fucharoen, S; Jirasomprasert, T; Jittangprasert, P; Limenta, LM; Morales, NP; Wilairat, P; Yamanont, P, 2011) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications." | 1.36 | Combined iron chelation therapy. ( Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW, 2010) |
| " However, despite these fatalities it would appear that there is no regular monitoring of such toxicities or of effects such as the accumulation of toxic metals." | 1.35 | Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. ( Kontoghiorghes, GJ, 2008) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "The parents of 18 thalassemia major patients (under 12 years of age) were interviewed (in two sessions) to determine their feelings, sources of stress, and support during their childrens' disease process." | 1.33 | Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY, 2006) |
| "Comprehensive care for thalassemia major (TM) patients has achieved great advances in the world, yet psychosocial developmental aspects of care in families with afflicted members has made only limited progress." | 1.33 | Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY; Wu, KH, 2006) |
| "We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (13.19) | 18.2507 |
| 2000's | 36 (39.56) | 29.6817 |
| 2010's | 41 (45.05) | 24.3611 |
| 2020's | 2 (2.20) | 2.80 |
| Authors | Studies |
|---|---|
| Georgiev, PG | 1 |
| Sapunarova, KG | 1 |
| Goranova-Marinova, VS | 1 |
| Goranov, SE | 1 |
| Chuang, TY | 1 |
| Li, JP | 1 |
| Weng, TF | 1 |
| Wu, KH | 8 |
| Chao, YH | 1 |
| Noureldine, MHA | 1 |
| Taher, AT | 2 |
| Haydar, AA | 1 |
| Berjawi, A | 1 |
| Khamashta, MA | 1 |
| Uthman, I | 1 |
| Mirlohi, MS | 1 |
| Yaghooti, H | 1 |
| Shirali, S | 1 |
| Aminasnafi, A | 1 |
| Olapour, S | 1 |
| Ghosh, K | 2 |
| Olivieri, NF | 4 |
| Sabouhanian, A | 1 |
| Gallie, BL | 1 |
| Viprakasit, V | 2 |
| Nuchprayoon, I | 1 |
| Chuansumrit, A | 2 |
| Torcharus, K | 1 |
| Pongtanakul, B | 1 |
| Laothamatas, J | 1 |
| Srichairatanakool, S | 1 |
| Pooliam, J | 2 |
| Supajitkasem, S | 1 |
| Suriyaphol, P | 1 |
| Tanphaichitr, VS | 2 |
| Tuchinda, S | 1 |
| Cermak, J | 1 |
| Jonasova, A | 1 |
| Vondrakova, J | 1 |
| Cervinek, L | 1 |
| Belohlavkova, P | 1 |
| Neuwirtova, R | 1 |
| Fisher, SA | 1 |
| Brunskill, SJ | 1 |
| Doree, C | 1 |
| Gooding, S | 1 |
| Chowdhury, O | 1 |
| Roberts, DJ | 2 |
| Origa, R | 2 |
| Danjou, F | 3 |
| Cossa, S | 1 |
| Matta, G | 1 |
| Bina, P | 2 |
| Dessì, C | 2 |
| Defraia, E | 2 |
| Foschini, ML | 2 |
| Leoni, G | 2 |
| Morittu, M | 2 |
| Galanello, R | 3 |
| de Witte, T | 1 |
| Jang, JH | 1 |
| Lee, JH | 1 |
| Yoon, SS | 1 |
| Jo, DY | 1 |
| Kim, HJ | 1 |
| Chung, J | 1 |
| Lee, JW | 1 |
| Bragadesh, T | 1 |
| Bhandari, S | 1 |
| Dee, CM | 1 |
| Cheuk, DK | 1 |
| Ha, SY | 2 |
| Chiang, AK | 1 |
| Chan, GC | 2 |
| Tanphaichitr, A | 1 |
| Kusuwan, T | 1 |
| Limviriyakul, S | 1 |
| Atipas, S | 1 |
| Sangpraypan, T | 1 |
| Calvaruso, G | 1 |
| Vitrano, A | 1 |
| Di Maggio, R | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Gerardi, C | 1 |
| Rigoli, LC | 1 |
| Sacco, M | 1 |
| Pitrolo, L | 1 |
| Maggio, A | 1 |
| Totadri, S | 1 |
| Bansal, D | 1 |
| Bhatia, P | 1 |
| Attri, SV | 1 |
| Trehan, A | 1 |
| Marwaha, RK | 1 |
| Moi, P | 1 |
| Follesa, I | 1 |
| Zappu, A | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Songdej, D | 1 |
| Sirachainan, N | 1 |
| Wongwerawattanakoon, P | 1 |
| Kadegasem, P | 1 |
| Sasanakul, W | 1 |
| Nijjar, PS | 1 |
| Vongooru, H | 1 |
| Tamene, A | 1 |
| Valeti, U | 1 |
| Masri, C | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Gomber, S | 1 |
| Jain, P | 1 |
| Sharma, S | 1 |
| Narang, M | 1 |
| Karimi, M | 1 |
| Avazpour, A | 1 |
| Haghpanah, S | 1 |
| Toosi, F | 1 |
| Badie, A | 1 |
| Kontoghiorghes, GJ | 9 |
| McLeod, C | 1 |
| Fleeman, N | 1 |
| Kirkham, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Chu, P | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Greenhalgh, J | 1 |
| Modell, B | 2 |
| Olujohungbe, A | 1 |
| Telfer, P | 1 |
| Walley, T | 1 |
| Farmaki, K | 1 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 2 |
| Berdoukas, V | 4 |
| Balocco, M | 1 |
| Carrara, P | 1 |
| Pinto, V | 1 |
| Forni, GL | 1 |
| Ladis, V | 3 |
| Moraitis, P | 1 |
| Zannikos, K | 1 |
| Berdoussi, E | 1 |
| Kattamis, C | 2 |
| Waalen, J | 1 |
| Evans, P | 1 |
| Kayyali, R | 1 |
| Hider, RC | 1 |
| Eccleston, J | 1 |
| Porter, JB | 1 |
| Hershko, C | 3 |
| Piga, A | 2 |
| Roggero, S | 1 |
| Salussolia, I | 1 |
| Massano, D | 1 |
| Serra, M | 1 |
| Longo, F | 1 |
| Agus, A | 1 |
| Campus, S | 1 |
| Giardina, PJ | 1 |
| Grady, RW | 1 |
| ElAlfy, MS | 1 |
| El Alfy, M | 1 |
| Sari, TT | 1 |
| Lee, CL | 1 |
| Tricta, F | 1 |
| El-Beshlawy, A | 2 |
| Limenta, LM | 1 |
| Jirasomprasert, T | 1 |
| Jittangprasert, P | 1 |
| Wilairat, P | 1 |
| Yamanont, P | 1 |
| Chantharaksri, U | 1 |
| Fucharoen, S | 1 |
| Morales, NP | 1 |
| Akrawinthawong, K | 1 |
| Chaowalit, N | 1 |
| Chatuparisuth, T | 1 |
| Siritanaratkul, N | 1 |
| Smith, GC | 1 |
| Alpendurada, F | 1 |
| Carpenter, JP | 1 |
| Alam, MH | 1 |
| Karagiorga, M | 1 |
| Aessopos, A | 1 |
| Gotsis, ED | 1 |
| Tanner, MA | 1 |
| Westwood, MA | 1 |
| Roughton, M | 1 |
| Pennell, DJ | 2 |
| Musallam, KM | 1 |
| Shuchman, M | 1 |
| Traynor, K | 1 |
| Fernandes, JL | 1 |
| Shah, J | 1 |
| Kurtin, SE | 1 |
| Arnold, L | 1 |
| Lindroos-Kolqvist, P | 1 |
| Tinsley, S | 1 |
| Hoffbrand, AV | 5 |
| Taher, A | 3 |
| Cappellini, MD | 1 |
| Efthimia, V | 1 |
| Neokleous, N | 1 |
| Agapidou, A | 1 |
| Economou, M | 1 |
| Vetsiou, E | 1 |
| Teli, A | 1 |
| Perifanis, V | 1 |
| Constantinou, G | 1 |
| Melides, S | 1 |
| Cohen, A | 1 |
| Ceci, A | 1 |
| Felisi, M | 1 |
| De Sanctis, V | 1 |
| De Mattia, D | 1 |
| Chang, JS | 2 |
| Tsai, CH | 4 |
| Peng, CT | 8 |
| Kattamis, A | 1 |
| Kassou, C | 1 |
| Berdousi, H | 1 |
| Papassotiriou, I | 1 |
| Victor Hoffbrand, A | 1 |
| Rund, D | 1 |
| Rachmilewitz, E | 1 |
| Rees, D | 1 |
| Howard, J | 1 |
| Hyde, C | 1 |
| Alderson, P | 1 |
| Brunskill, S | 1 |
| Link, G | 1 |
| Konijn, AM | 1 |
| Cabantchik, ZI | 1 |
| Neufeld, EJ | 1 |
| Chen, AC | 1 |
| Wu, SF | 3 |
| Chiang, IP | 1 |
| Kolnagou, A | 3 |
| Economides, C | 1 |
| Eracleous, E | 1 |
| Huang, YC | 1 |
| Chang, JG | 1 |
| Ho, YJ | 1 |
| Wang, CH | 1 |
| Tsai, FJ | 1 |
| Chik, KW | 1 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Mudiyanse, RM | 1 |
| Kuo, HT | 2 |
| Tsai, MY | 2 |
| Delea, TE | 1 |
| Edelsberg, J | 1 |
| Sofrygin, O | 1 |
| Thomas, SK | 1 |
| Baladi, JF | 1 |
| Phatak, PD | 1 |
| Coates, TD | 1 |
| Goldberg, SL | 1 |
| Manz, C | 1 |
| Naja, M | 1 |
| Eltagui, M | 1 |
| Tarabishi, C | 1 |
| Youssry, I | 1 |
| Sobh, H | 1 |
| Hamdy, M | 1 |
| Sharaf, I | 1 |
| Mostafa, A | 1 |
| Shaker, O | 1 |
| Kersten, MJ | 1 |
| Lange, R | 1 |
| Smeets, ME | 1 |
| Vreugdenhil, G | 1 |
| Roozendaal, KJ | 1 |
| Lameijer, W | 1 |
| Goudsmit, R | 2 |
| Diav-Citrin, O | 1 |
| Koren, G | 3 |
| AL-Refaie, F | 1 |
| Davis, B | 1 |
| Siritanakatkul, N | 1 |
| Jackson, BF | 1 |
| Cochrane, J | 1 |
| Prescott, E | 1 |
| Wonke, B | 2 |
| Wright, C | 1 |
| Barman Balfour, JA | 1 |
| Foster, RH | 1 |
| Lucas, GN | 1 |
| Perera, BJ | 1 |
| Fonseka, EA | 1 |
| De Silva, DD | 1 |
| Fernandopulle, M | 1 |
| Pippard, MJ | 1 |
| Weatherall, DJ | 1 |
| Pattichi, K | 1 |
| Hadjigavriel, M | 1 |
| Bohane, T | 1 |
| Eagle, C | 1 |
| Lindeman, R | 1 |
| DeSilva, K | 1 |
| Tobias, V | 1 |
| Painter, D | 1 |
| Fraser, I | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Inati, A | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Chandy, M | 1 |
| Agarwal, MB | 1 |
| Gupte, SS | 1 |
| Vasandani, D | 1 |
| Viswanathan, C | 1 |
| Puniyani, RR | 1 |
| Ramanathan, J | 1 |
| Massil, DE | 1 |
| Shah, S | 1 |
| Rajyadhyaksha, GC | 1 |
| Bhave, AA | 1 |
| St Louis, P | 1 |
| Freedman, MH | 2 |
| McClelland, RA | 2 |
| Templeton, DM | 2 |
| Chung, D | 1 |
| Hermann, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498] | 75 participants (Anticipated) | Observational | 2017-12-01 | Not yet recruiting | |||
| A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia[NCT00529152] | Phase 3 | 100 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Platelet Changes in Cases of Iron Overload(IO)[NCT04329377] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506] | 50 participants (Anticipated) | Observational | 2022-07-02 | Not yet recruiting | |||
| Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662] | Phase 3 | 95 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study (NCT00529152)
Timeframe: Baseline and 24 weeks
| Intervention | ug/L (Mean) |
|---|---|
| Ferriprox Oral Solution | -355.5 |
Number of Adverse Events over 24 weeks (NCT00529152)
Timeframe: 24 Weeks
| Intervention | Adverse Events (Number) |
|---|---|
| Ferriprox Oral Solution | 212 |
25 reviews available for deferiprone and Transfusion Reaction
| Article | Year |
|---|---|
Rheumatological complications of beta-thalassaemia: an overview.
Topics: Arthritis; beta-Thalassemia; Blood Transfusion; Connective Tissue Diseases; Deferiprone; Femur Head | 2018 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2013 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
Iron chelation therapy for transfusional iron overload: a swift evolution.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload | 2011 |
Deferiprone (Ferriprox) for iron overload.
Topics: Animals; Clinical Trials as Topic; Deferiprone; Humans; Iron Overload; Pyridones; Thalassemia; Trans | 2012 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2012 |
Role of deferiprone in chelation therapy for transfusional iron overload.
Topics: Chelation Therapy; Deferiprone; Humans; Iron Overload; Pyridones; Transfusion Reaction; Treatment Ou | 2003 |
Pharmacotherapy of iron overload in thalassaemic patients.
Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I | 2003 |
Deferiprone therapy for transfusional iron overload.
Topics: Chelation Therapy; Clinical Trials as Topic; Deferiprone; Dose-Response Relationship, Drug; Heart Di | 2005 |
Beta-thalassemia.
Topics: Antioxidants; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Hematopoietic Ste | 2005 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; | 2005 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis | 2006 |
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; | 2006 |
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron C | 2007 |
Long-term therapy with deferiprone.
Topics: Animals; Clinical Trials as Topic; Deferiprone; Drug Approval; Hemosiderosis; Humans; Iron; Iron Che | 1996 |
Oral iron chelation with deferiprone.
Topics: Acute Disease; Administration, Oral; Anemia; Chelation Therapy; Child; Deferiprone; Humans; Iron Ove | 1997 |
Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Topics: beta-Thalassemia; Clinical Trials as Topic; Deferiprone; Humans; Iron; Iron Chelating Agents; Pyrido | 1999 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2000 |
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reac | 2000 |
Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia.
Topics: Chelating Agents; Deferiprone; Drug Design; Humans; Iron; Iron Chelating Agents; Pyridines; Pyridone | 1990 |
18 trials available for deferiprone and Transfusion Reaction
| Article | Year |
|---|---|
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Topics: Acute Disease; Administration, Oral; Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferipr | 2013 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
Topics: Administration, Oral; Agranulocytosis; Anemia, Sickle Cell; beta-Thalassemia; Chemistry, Pharmaceuti | 2010 |
Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiovascular Abnormalities; Deferiprone; Echocardiography, Do | 2011 |
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Defe | 2003 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin | 2008 |
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Female; Ferritins; Hemosiderosis; Huma | 1996 |
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelating | 1998 |
Combined therapy with deferiprone and desferrioxamine.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr | 1998 |
A trial of deferiprone in transfusion-dependent iron overloaded children.
Topics: Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Ferritins; Humans; Iron Chelatin | 2000 |
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Topics: Adolescent; Chelation Therapy; Deferiprone; Hemochromatosis; Humans; Iron Chelating Agents; Pyridone | 1991 |
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug A | 1990 |
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Topics: Administration, Oral; Adult; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridon | 1990 |
48 other studies available for deferiprone and Transfusion Reaction
| Article | Year |
|---|---|
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin | 2020 |
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Moda | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Topics: Administration, Oral; Anemia, Diamond-Blackfan; beta-Thalassemia; Blood Transfusion; Deferasirox; De | 2019 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferr | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Mye | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Age | 2013 |
Deferiprone, iron overload in a renal transplant patient.
Topics: Aged; Deferiprone; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Transplantation; | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; | 2014 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I | 2015 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Topics: Anemia, Hemolytic; Child; Child, Preschool; Deferiprone; Female; Ferritins; Humans; Iron Chelating A | 2016 |
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Topics: Adult; Anemia, Aplastic; Deferiprone; Deferoxamine; Echocardiography; Hemochromatosis; Humans; Iron | 2015 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; De | 2017 |
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; | 2008 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
More pieces to the iron chelation puzzle.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Over | 2010 |
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; | 2010 |
Deferiprone.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones; Randomized Control | 2010 |
Combined iron chelation therapy.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans | 2010 |
Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Topics: Administration, Oral; Adult; Area Under Curve; beta-Thalassemia; Deferiprone; Female; Ferritins; Hem | 2011 |
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; | 2011 |
FDA panel recommends approval of deferiprone.
Topics: Agranulocytosis; Deferiprone; Drug Approval; Drug Labeling; Humans; Iron Chelating Agents; Off-Label | 2011 |
Deferiprone approved for iron overload.
Topics: Deferiprone; Drug Approval; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thal | 2011 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferip | 2013 |
The Olivieri case.
Topics: Deferiprone; Drug Approval; Interinstitutional Relations; Iron Chelating Agents; Iron Overload; Pyri | 2003 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design | 2006 |
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chelatio | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T | 2006 |
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap | 2006 |
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Atti | 2006 |
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalass | 2006 |
The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).
Topics: Australia; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reactio | 2000 |
Iron chelation.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; | 1991 |
[Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Deferiprone; Female; Ferritins; Hemosiderosis; Humans; I | 1991 |